GLP-1 medicines have moved from a specialist diabetes treatment into mainstream weight-management conversations. Adoption is now being influenced by clinical need, obesity prevalence, easier access, social media, telehealth and growing public awareness.
The trend is particularly visible among U.S. adults, while the UK and China are becoming important international growth opportunities.
See the bigger picture across company moves, investments, sales and consumer needs. Download Sample: https://www.towardshealthcare.com/download-sample/5129
Where Is GLP-1 Use Increasing Most?
The United States is currently the clearest example of rapid GLP-1 adoption.
A 2025 consumer analysis reported that 18% of U.S. adults had used GLP-1 drugs as of June 2025, compared with 12% in 2024.
CDC data show that in 2024, 26.5% of U.S. adults with diagnosed diabetes used GLP-1 injectable medicines, equivalent to approximately 6.9 million people.
U.S. GLP-1 Consumer Data
- 18% of U.S. adults reported GLP-1 use in June 2025, up from 12% in 2024.
- 26.5% of U.S. adults with diagnosed diabetes used GLP-1 injectables in 2024.
- This represented approximately 6.9 million adults.
- Use was 33.3% among adults aged 50–64.
- Use was 29.7% among adults aged 35–49.
- Use was 25.3% among adults aged 18–34.
- Among adults with diagnosed diabetes and obesity, GLP-1 injectable use reached 32.4%.
This suggests that the biggest established consumer base is not simply young people seeking cosmetic weight loss. Middle-aged adults, people with diabetes and adults living with obesity represent major clinical demand.
Who Are the Actual GLP-1 Consumers?
The consumer base is becoming increasingly diverse.
1. Adults Living With Obesity
Adults with obesity represent one of the largest medically relevant populations.
CDC data show GLP-1 injectable use among adults with diagnosed diabetes increased from 7.6% in 2018 to 19.4% in 2022, a 155% increase. Spending on GLP-1 medicines increased by more than 500% between 2018 and 2023.
2. Adults With Type 2 Diabetes
GLP-1 medicines were initially established primarily through diabetes treatment.
In 2024, approximately 6.9 million U.S. adults with diagnosed diabetes were estimated to be using GLP-1 injectables.
3. Younger Adults
Younger adults are also entering the category, although their usage remains lower than among middle-aged adults.
Among U.S. adults with diagnosed diabetes, 25.3% of those aged 18–34 used GLP-1 injectables in 2024.
4. Celebrities, Film Actors and Public Figures
Celebrity visibility has become an important awareness and demand driver, although celebrity use should never be treated as evidence that treatment is appropriate for the general population.
A December 2025 compilation documented 95 public figures who had discussed GLP-1 medicines, including people reporting positive experiences, side effects, skepticism or concerns about social pressure.
Publicly disclosed examples include:
- A U.S. actress reported losing more than 63 pounds while using a GLP-1 medicine alongside exercise and weight training.
- A U.S. professional athlete publicly reported losing more than 31 pounds using a GLP-1 medicine after struggling with postpartum weight management.
- A U.S. television personality reported losing 12 pounds within two weeks after beginning tirzepatide for diabetes, although this was not initially prescribed specifically for weight loss.
- Another U.S. television personality reported losing 25 pounds after using a GLP-1 and said it helped reduce cravings.
- A U.S. media personality reported regaining 20 pounds during a 12-month period after stopping GLP-1 treatment, highlighting the importance of long-term weight management.
Celebrity influence can also translate into measurable consumer behavior. Zocdoc data reported that weight-loss-drug appointments increased 29% after one celebrity disclosure, 27% after another public campaign, 18% following a major television interview, and 6% following another celebrity disclosure.
Important: these are self-reported public accounts, not clinical evidence, and they should not be generalized to ordinary patients.
Country-Wise Celebrity and Public-Figure Influence
Public disclosure is considerably better documented in the U.S. and UK than in many other countries. In countries such as India, dramatic weight loss is frequently attributed to GLP-1 medicines online without confirmation, so those claims should not be counted as real GLP-1 users.
United States
The U.S. has the largest concentration of publicly documented celebrity GLP-1 discussions.
- Multiple actors, television personalities, athletes and media figures have publicly discussed GLP-1 use.
- Individual reported weight-loss outcomes include 25 pounds, 31+ pounds, 63+ pounds and 12 pounds in two weeks.
- Celebrity disclosures have been associated with measurable increases in weight-loss-drug appointments.
United Kingdom
The UK has a rapidly expanding GLP-1 conversation involving actors, television personalities, influencers and public figures.
However, the more important evidence is the underlying consumer base: a study of 5,893 adults in Great Britain estimated that 1.6 million adults had used a GLP-1 or GLP-1/GIP medicine for weight loss during the previous year, including approximately 910,000 people who used them exclusively for weight loss.
Private prescribing is also significant. The Health Foundation analyzed 113,630 patients who received a private GLP-1 weight-loss prescription from an online provider between November 2024 and October 2025.
The UK’s celebrity influence therefore sits alongside a large and increasingly measurable real-world patient population.
India
India has a rapidly growing public conversation around GLP-1 medicines, particularly among Bollywood and social-media audiences.
However, celebrity GLP-1 use is difficult to verify. Several Indian public figures have been the subject of online Ozempic speculation, while some have explicitly denied using the medicines. For example, a major Indian film personality publicly rejected Ozempic claims and attributed a 20-kg weight loss to sustained lifestyle changes.
Therefore, celebrity transformation statistics from India should not be presented as confirmed GLP-1 usage unless the individual has publicly confirmed it.
India’s stronger measurable signal is pharmaceutical demand: reporting citing industry data indicated that sales of Ozempic and related weight-loss medicines increased from approximately ₹137 crore in 2020 to ₹535 crore in 2024.
Australia
Australia has also seen increasing public discussion around GLP-1 medicines, but publicly verified celebrity-use data are less extensive than in the U.S.
The Australian regulator classifies GLP-1 and dual GIP/GLP-1 medicines as high-profile treatments used for type 2 diabetes and/or obesity and has issued safety communications concerning their use.
For Australia, patient prescribing, obesity prevalence and regulatory data are more reliable indicators of opportunity than celebrity disclosures.
Canada
Canada is another important GLP-1 opportunity, but celebrity-specific usage data are limited.
Health Canada issued a 2026 warning about unauthorized and counterfeit GLP-1 products, showing that consumer demand has become significant enough to attract illegal online sellers.
Again, verified patient-use and prescription data provide a stronger basis for evaluating Canadian demand than celebrity stories.
GLP-1 Adoption Is Also Creating a New Consumer Segment
The growth of GLP-1 therapy is creating demand beyond pharmaceutical products.
Users are increasingly looking for:
- High-protein foods
- Smaller portion sizes
- Nutrition support
- Exercise and strength training
- Supplements
- Beauty and skincare products
- Telehealth services
- Weight-maintenance programs
- Convenient oral treatments
Contact us for more: https://www.towardshealthcare.com/contact-us
Food companies are already responding. Recent reporting indicates that Conagra and General Mills are developing products around changing GLP-1 consumer preferences, including higher-protein and portion-controlled foods. Some analysts estimate that GLP-1 medicines could be used by up to 55 million Americans by 2035.
Where Is GLP-1 Treatment Growing Outside the U.S.?
United Kingdom: Rapidly Expanding Consumer Adoption
The UK is becoming one of the clearest international GLP-1 growth markets.
A population study of 5,893 adults in Great Britain found:
- 4.5% had used a GLP-1 or GLP-1/GIP medicine during the previous year.
- 2.9% had used one to support weight loss.
- 1.7% had used the medicines exclusively for weight loss.
- Approximately 1.6 million adults were estimated to have used GLP-1 or GLP-1/GIP medicines for weight loss.
- Approximately 910,000 were estimated to have used them exclusively for weight loss.
The UK has now entered another phase of innovation: oral GLP-1 treatment. Eli Lilly launched its once-daily oral GLP-1 medicine Foundayo (orforglipron) in UK pharmacies in August 2026, making the UK the first European country where the product is available.
China: A Major Future Opportunity
China is emerging as another important growth region.
Recent reporting projects that more than 65% of China’s population could be overweight or obese by 2030, increasing potential demand for obesity-management treatments.
Novo Nordisk, Eli Lilly, Pfizer and Chinese companies are increasing their focus on China’s obesity-treatment opportunity.
The Chinese GLP-1 opportunity is also being influenced by social media, peer recommendations, public awareness and increasing demand for weight-management treatment.
Regional Consumer Opportunity
| Region / Country | Real consumer data | GLP-1 opportunity |
|---|---|---|
| U.S. | 18% of adults reported GLP-1 use in June 2025 | Largest established consumer opportunity |
| U.S. – Diabetes | 26.5% of adults with diagnosed diabetes used GLP-1 injectables in 2024 | Strong clinical demand |
| Great Britain | 1.6M adults estimated to have used GLP-1 medicines for weight loss | Rapid private and healthcare adoption |
| China | >65% of population projected overweight/obese by 2030 | Major future patient opportunity |
| India | GLP-1-related drug sales reported at ₹535 crore in 2024, up from ₹137 crore in 2020 | Fast-growing consumer awareness |
| Australia | GLP-1s officially recognized for diabetes and/or obesity treatment | Expanding prescription opportunity |
| Canada | Health Canada warning on unauthorized GLP-1 products indicates strong consumer demand | Growing access and safety focus |
| Europe | Oral GLP-1 availability expanding, beginning with the UK | Major next-stage opportunity |
Which Consumer Groups Are Driving the Trend?
The data suggest several distinct groups are driving GLP-1 adoption:
Clinical consumers: Adults with obesity, type 2 diabetes and obesity-related conditions.
Middle-aged adults: U.S. data show the highest GLP-1 injectable use among diagnosed-diabetes patients aged 50–64, at 33.3%.
Younger adults: Usage is already measurable among adults aged 18–34, at 25.3% among those with diagnosed diabetes.
Private-pay consumers: Particularly important in the UK, where private prescribing has expanded significantly.
Celebrity and social-media audiences: Public disclosures can influence awareness and appointment demand, but this group should not be confused with the medically indicated patient population.
What Is Increasing GLP-1 Demand?
Several factors are working together:
- Rising obesity prevalence
- Type 2 diabetes
- Greater physician awareness
- Strong clinical evidence
- Celebrity visibility
- Social-media discussion
- Telehealth prescribing
- Private-pay access
- New oral GLP-1 medicines
- Increasing competition among pharmaceutical companies
The next major shift could come from oral GLP-1 therapies. The UK has already become an important launch market for this trend, with both oral Wegovy and Eli Lilly’s Foundayo expanding non-injectable treatment options.
What Companies Should Focus On
Pharmaceutical and healthcare companies should focus on:
- Identifying the highest-growth patient groups
- Tracking regional GLP-1 adoption
- Improving affordability and insurance access
- Developing oral and less-frequent dosing
- Addressing gastrointestinal tolerability
- Supporting long-term adherence
- Understanding consumer nutrition needs
- Monitoring telehealth and private-prescription channels
- Building evidence across obesity-related diseases
- Separating medically appropriate use from lifestyle-driven demand
The biggest opportunity is no longer simply selling another GLP-1 drug. It is understanding who is adopting these treatments, why they are using them, where demand is concentrated and what patients need throughout long-term treatment.
How Towards Healthcare Can Help
Towards Healthcare Research & Consulting can help companies track:
- GLP-1 patient and consumer intelligence
- Country-level adoption
- Obesity and diabetes populations
- Prescribing trends
- Competitor sales and revenue
- Drug launches and clinical trials
- Regional opportunities
- Buyer and payer intelligence
- Telehealth prescribing
- Patient affordability
- Consumer behavior after GLP-1 treatment
- Nutrition, fitness and wellness opportunities
This creates a broader view of the GLP-1 ecosystem by connecting patient demand, regional data, pharmaceutical competition, consumer behavior and investment opportunities.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium